Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5656765 | Médecine des Maladies Métaboliques | 2017 | 8 Pages |
Abstract
After 32 weeks of treatment, STEP was non inferior to FULL in terms of HbA1c change (mean treatment difference: 0.14 [CI 95%: -0.02; 0.30]). Significantly fewer hypoglycemic episodes occurred in the STEP group. In addition, treatment-emergent adverse events did not differ among groups.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
H.-W. Rodbard, V.-E. Visco, H. Andersen, L.-C. Hiort, D.-H.W. Shu,